1So, FV, Guthrie, N, Chambers, AF, et al. (1996) Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 26, 167–181.
2Leonardi, T, Vanamala, J, Taddeo, SS, et al. (2010) Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats. Exp Biol Med (Maywood) 235, 710–717.
3Miller, EG, Peacock, JJ, Bourland, TC, et al. (2008) Inhibition of oral carcinogenesis by citrus flavonoids. Nutr Cancer 60, 69–74.
4Ekambaram, G, Rajendran, P, Magesh, V, et al. (2008) Naringenin reduces tumor size and weight lost in N-methyl-N′-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Nutr Res 28, 106–112.
6EPA (1990) Aerometric Information Retrieval System (AIRS), Data for 1985–1990 [Agency, EP, editor]. Research Triangle Park, NC: US Environmental Protection Agency.
7Gonzalez, FJ & Gelboin, HV (1994) Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26, 165–183.
8Dertinger, SD, Lantum, HB, Silverstone, AE, et al. (2000) Effect of 3′-methoxy-4′-nitroflavone on benzo[a]pyrene toxicity. Aryl hydrocarbon receptor-dependent and -independent mechanisms. Biochem Pharmacol 60, 189–196.
9Kronenberg, S, Esser, C & Carlberg, C (2000) An aryl hydrocarbon receptor conformation acts as the functional core of nuclear dioxin signaling. Nucleic Acids Res 28, 2286–2291.
10Safe, S (2001) Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 120, 1–7.
11Shimizu, Y, Nakatsuru, Y, Ichinose, M, et al. (2000) Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A 97, 779–782.
12Buters, JT, Sakai, S, Richter, T, et al. (1999) Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci U S A 96, 1977–1982.
13Zheng, W, Xie, DW, Jin, F, et al. (2000) Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9, 147–150.
14Helmig, S, Seelinger, JU, Dohrel, J, et al. (2011) RNA expressions of AHR, ARNT and CYP1B1 are influenced by AHR Arg554Lys polymorphism. Mol Genet Metab 104, 180–184.
15Paracchini, V, Raimondi, S, Gram, IT, et al. (2007) Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol 165, 115–125.
16Economopoulos, KP & Sergentanis, TN (2010) Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122, 545–551.
17Phillips, DH (1999) Polycyclic aromatic hydrocarbons in the diet. Mutat Res 443, 139–147.
18Tsuchiya, Y, Nakajima, M & Yokoi, T (2003) Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J Biochem 133, 583–592.
19Tsuchiya, Y, Nakajima, M, Kyo, S, et al. (2004) Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 64, 3119–3125.
20Bovee, TF, Schoonen, WG, Hamers, AR, et al. (2008) Screening of synthetic and plant-derived compounds for (anti)estrogenic and (anti)androgenic activities. Anal Bioanal Chem 390, 1111–1119.
21Wang, HK, Yeh, CH, Iwamoto, T, et al. (2012) Dietary flavonoid naringenin induces regulatory T cells via an aryl hydrocarbon receptor mediated pathway. J Agric Food Chem 60, 2171–2178.
22Ciolino, HP & Yeh, GC (1999) The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br J Cancer 79, 1340–1346.
23Livak, KJ & Schmittgen, TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2( − Delta Delta C(T)) method. Methods 25, 402–408.
24Chan, HY, Wang, H & Leung, LK (2003) The red clover (Trifolium pratense) isoflavone biochanin A modulates the biotransformation pathways of 7,12-dimethylbenz[a]anthracene. Br J Nutr 90, 87–92.
25Doostdar, H, Burke, MD & Mayer, RT (2000) Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144, 31–38.
26Hughes, D, Guttenplan, JB, Marcus, CB, et al. (2008) Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation. Cancer Prev Res (Phila) 1, 485–493.
27Tang, YM, Wo, YY, Stewart, J, et al. (1996) Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 271, 28324–28330.
28Sun, YV, Boverhof, DR, Burgoon, LD, et al. (2004) Comparative analysis of dioxin response elements in human, mouse and rat genomic sequences. Nucleic Acids Res 32, 4512–4523.
29Kaczynski, JA, Conley, AA, Fernandez Zapico, M, et al. (2002) Functional analysis of basic transcription element (BTE)-binding protein (BTEB) 3 and BTEB4, a novel Sp1-like protein, reveals a subfamily of transcriptional repressors for the BTE site of the cytochrome P4501A1 gene promoter. Biochem J 366, 873–882.
30Wo, YY, Stewart, J & Greenlee, WF (1997) Functional analysis of the promoter for the human CYP1B1 gene. J Biol Chem 272, 26702–26707.
31Delescluse, C, Lemaire, G, de Sousa, G, et al. (2000) Is CYP1A1 induction always related to AHR signaling pathway? Toxicology 153, 73–82.
32Kikuchi, H, Hossain, A, Yoshida, H, et al. (1998) Induction of cytochrome P-450 1A1 by omeprazole in human HepG2 cells is protein tyrosine kinase-dependent and is not inhibited by alpha-naphthoflavone. Arch Biochem Biophys 358, 351–358.
33Liehr, JG (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21, 40–54.
34Shimada, T, Hayes, CL, Yamazaki, H, et al. (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56, 2979–2984.
35Peter Guengerich, F, Chun, YJ, Kim, D, et al. (2003) Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 523–524, 173–182.
36Vallejo, F, Larrosa, M, Escudero, E, et al. (2010) Concentration and solubility of flavanones in orange beverages affect their bioavailability in humans. J Agric Food Chem 58, 6516–6524.